Jeffrey Wager, M.D.
Chairman & CEOExecutive Assistant: anna.rabinovych(at)enbiotix-dot-com
Jeffrey Wager has 23 years of senior operating experience in the life sciences, beginning his career with a unit of the Bank of Tokyo, advising Japanese pharma companies on the design and conduct of international clinical trials and strategic alliances. He then was part of Medical Science Partners, a $100 million Harvard sponsored VC fund focused on startups spinning out of the Harvard medical system, helping to create and manage a portfolio of 30 companies.
In 2000, he formed Apeiron Partners LLC, focusing on corporate spin-outs and VC funds, where he was intimately involved in the design, launch and investment of Z-Cube (€60 million fund created by the Zambon Group in Italy) and the design/execution of six corporate spin-outs - including Targacept, Inc. (NASD:TRGT) and Artisan Pharma, Inc., the latter also as its founding CEO between 2006-2010, raising $50 million, building the entire team and implementing a 750 patient, 17 country Phase 2b/3 study ultimately leading to Artisan’s acquisition by Asahi in 2011.
Dr. Wager is a co-founder and chairman of Proterris, Inc., a therapeutic medical gases company, and an observer to the board of Biotoscana, SL, the largest private equity-backed specialty pharma company in Latin America (2014 revenues - $200 million), which he was instrumental in forming by advising United Medical, Ltda. of Sao Paulo, Brazil on its sale to Biotoscana.
Jeffrey Wager, M.D.
Chairman & CEO
Chief Business OfficerMike.Garrett(at)EnBiotix-dot-com
Mr. Garrett is responsible for formulation and execution of corporate and strategic development at EnBiotix, in addition to managing the legal group. He has more than 25 years experience in the life sciences industry working in business development, investment management, licensing and intellectual property positions for large companies, venture funds and entrepreneurial biopharma groups.
From 2006 to 2014 Mr. Garrett was Vice President of Corporate and Strategic Development at Scynexis, Inc., most recently as a member of the team that executed the company’s $62M IPO. From 2004 to 2006, Mr. Garrett was a Managing Director of Pharmavent Partners, a European Life Sciences venture capital fund headquartered in Paris, where he was responsible for UK-based investment opportunities. From 2001 to 2004, he was Global Vice President, Ventures &amp;amp; Business Development for BTG plc, a FTSE-250 company with responsibility for the company’s portfolio of 15 investments in early stage to public companies. Prior to this Mr. Garrett worked in the corporate venture group of Aventis (Paris) and in their business development group. Earlier in his career he was a patent attorney in the Rhone-Poulenc Intellectual Property department, based in France and the UK.
Mr. Garrett is a British and European Patent Attorney, holds an Honors degree in Chemistry from Southampton University, UK and an Executive Certificate in General Management from the Cedep-INSEAD business school, France.
Chief Business Officer
Diane Joseph-McCarthy, Ph.D.
Vice President, Translational Sciencediane.j-m(at)enbiotix-dot-com
Diane Joseph-McCarthy is Vice President of Discovery &amp;amp; Pre-Clinical Development at EnBiotix, with more than 17 years drug discovery and leadership experience in the pharmaceutical and biotechnology sector.
Before joining EnBiotix, she was an Associate Director in Infection Chemistry at AstraZeneca, where she led an innovative group of scientists with impact across the discovery value chain. In this role, she initiated and led a global team, across three international sites, as part of a key capability build in Predictive Science. This effort also involved managing several external collaborations. She also either led or was a member of several task forces aimed at transforming Infection’s early portfolio.
Prior to that, Dr. Joseph-McCarthy was at Wyeth, as the Cambridge Site Head for Computational Chemistry, where she worked across therapeutic areas. She has been actively involved in the discovery of several compounds that have reached clinical trials. Dr. Joseph-McCarthy received her BA from Boston University, and her PhD from MIT with Professors Gregory A. Petsko and Martin Karplus (Nobel Laureate). Following her dissertation, she was a Research Fellow at Harvard Medical School, with fellowships from the Radcliffe Bunting Institute, the Charles A. King Medical Foundation, and the Giovanni Armenise-Harvard Foundation.
Dr. Joseph-McCarthy has more than 65 publications and patents, and has given numerous invited talks. She has served as a member of the National Academies of Sciences Polio Antiviral Advisory Committee, and is currently a member of the editorial advisory board for two international journals.
Diane Joseph-McCarthy, Ph.D.
Vice President, Translational Science
Jeffrey Radding, Ph.D.
Vice President, Biologyjeff.radding(at)enbiotix-dot-com
Jeffrey Radding brings 24 years of drug discovery and biotechnology experience to EnBiotix.
In his previous position as VP of R+D at Epitome Biosystems, Dr. Radding and his team developed and commercialized multiplex assay platforms for drug discovery, quantifying site-specific protein phosphorylation for discovery, biomarker and diagnostic applications (EpiQuant™, EMD Millipore).
Prior to joining Epitome, Dr. Radding was at Eli Lilly. Dr. Radding was Group Leader in the Cell Signaling Group in Platform Biology and Project Team Leader in Cancer Research. In Infectious Diseases Research, Dr. Radding was Project Team Leader for the discovery and development of the antifungal LY295337 through Phase I and was a key member on the discovery team for LY303366 (Eraxis™, Pfizer, Inc.).
Dr. Radding did his postdoctoral studies at the MacArthur Center for Molecular Parasitology at Yale University School of Medicine, focusing on the biology of Pneumocystis carinii and Trypanosoma and their ability to escape immune clearance. He received his doctorate in Biological Chemistry at Indiana University and his baccalaureate in Chemistry at Boston University.
Jeffrey Radding, Ph.D.
Vice President, Biology
Benjamin Perrone, Ph.D.
Manager, Business Developmentben.perrone(at)enbiotix-dot-com
Benjamin Perrone has over eight years of biomedical research, development, and translation experience. Before joining EnBiotix, he worked as Senior Associate, New Ventures in the Boston University Office of Technology Development, where he helped spin out six NewCos built around Boston University technologies in the life sciences, med tech, and healthcare I.T. spaces, and built a new application and evaluation process for the Ignition gap funding award program, with templates later incorporated by the BU Coulter Foundation Award and by the NSF SBIR program.
He is also a Program Leader at the Boston chapter of the Startup Leadership Program, an angel-sponsored training program for outstanding startup founders and innovators, and splits his free time between kite-surfing and bridge. He received his Ph.D. in Biomedical Engineering from Boston University, and a B.A. with Honors in Physics from the University of Chicago.